Table of Content
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Global Glioblastoma Multiforme Market
2.1.1. Global Glioblastoma Multiforme Market, By Surgery
2.1.2. Global Glioblastoma Multiforme Market, By End-User
2.1.3. Global Glioblastoma Multiforme Market, By Drug Class
2.1.4. Global Glioblastoma Multiforme Market, By Immunotherapy Agents
2.1.5. Global Glioblastoma Multiforme Market, By Targeted Therapy Agents
2.1.6. Global Glioblastoma Multiforme Market, By Clinical Trial Phase
2.1.7. Global Glioblastoma Multiforme Market, By Diagnostic Tools
2.1.8. Global Glioblastoma Multiforme Market, By Region
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Glioblastoma Multiforme Market Value, 2019-2032, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Glioblastoma Multiforme Market Drivers
3.2.2. Glioblastoma Multiforme Market Restraints
3.2.3. Glioblastoma Multiforme Market Opportunities
3.2.4. Major Glioblastoma Multiforme Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Surgery
3.5.2. End-User
3.5.3. Drug Class
3.5.4. Immunotherapy Agents
3.5.5. Targeted Therapy Agents
3.5.6. Clinical Trial Phase
3.5.7. Diagnostic Tools
3.5.8. Geography
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2023
4.1.1. Global Glioblastoma Multiforme Market: Company Market Share, Value 2023
4.1.2. Global Glioblastoma Multiforme Market: Top 6 Company Market Share, Value 2023
4.1.3. Global Glioblastoma Multiforme Market: Top 3 Company Market Share, Value 2023
4.2. Global Glioblastoma Multiforme Market: Company Revenue Share Analysis, 2023
4.3. Company Assessment Metrics, 2023
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2023
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Glioblastoma Multiforme Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2023
6.1. Company market share of key players, 2023
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Glioblastoma Multiforme Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. Global Glioblastoma Multiforme Market, By Surgery
8.1. Global Glioblastoma Multiforme Market Overview, by Surgery
8.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Surgery, 2023 Vs 2032 (in %)
8.2. Radiation Therapy
8.2.1. Global Glioblastoma Multiforme Market, By Radiation Therapy, By Region, 2019-2032 (US$ Mn)
8.2.2. Market Dynamics for Radiation Therapy
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Chemotherapy
8.3.1. Global Glioblastoma Multiforme Market, By Chemotherapy, By Region, 2019-2032 (US$ Mn)
8.3.2. Market Dynamics for Chemotherapy
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Immunotherapy
8.4.1. Global Glioblastoma Multiforme Market, By Immunotherapy, By Region, 2019-2032 (US$ Mn)
8.4.2. Market Dynamics for Immunotherapy
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Targeted Therapy
8.5.1. Global Glioblastoma Multiforme Market, By Targeted Therapy, By Region, 2019-2032 (US$ Mn)
8.5.2. Market Dynamics for Targeted Therapy
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
8.6. Tumor Treating Fields (TTF) Therapy
8.6.1. Global Glioblastoma Multiforme Market, By Tumor Treating Fields (TTF) Therapy, By Region, 2019-2032 (US$ Mn)
8.6.2. Market Dynamics for Tumor Treating Fields (TTF) Therapy
8.6.2.1. Drivers
8.6.2.2. Restraints
8.6.2.3. Opportunities
8.6.2.4. Trends
8.7. Supportive Care
8.7.1. Global Glioblastoma Multiforme Market, By Supportive Care, By Region, 2019-2032 (US$ Mn)
8.7.2. Market Dynamics for Supportive Care
8.7.2.1. Drivers
8.7.2.2. Restraints
8.7.2.3. Opportunities
8.7.2.4. Trends
9. Global Glioblastoma Multiforme Market, By End-User
9.1. Global Glioblastoma Multiforme Market Overview, by End-User
9.1.1. Global Glioblastoma Multiforme Market Revenue Share, By End-User, 2023 Vs 2032 (in %)
9.2. Hospitals
9.2.1. Global Glioblastoma Multiforme Market, By Hospitals, By Region, 2019-2032 (US$ Mn)
9.2.2. Market Dynamics for Hospitals
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Cancer Research Institutes
9.3.1. Global Glioblastoma Multiforme Market, By Cancer Research Institutes, By Region, 2019-2032 (US$ Mn)
9.3.2. Market Dynamics for Cancer Research Institutes
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Ambulatory Surgical Centers
9.4.1. Global Glioblastoma Multiforme Market, By Ambulatory Surgical Centers, By Region, 2019-2032 (US$ Mn)
9.4.2. Market Dynamics for Ambulatory Surgical Centers
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
9.5. Others
9.5.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
9.5.2. Market Dynamics for Others
9.5.2.1. Drivers
9.5.2.2. Restraints
9.5.2.3. Opportunities
9.5.2.4. Trends
10. Global Glioblastoma Multiforme Market, By Drug Class
10.1. Global Glioblastoma Multiforme Market Overview, by Drug Class
10.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Drug Class, 2023 Vs 2032 (in %)
10.2. Temozolomide
10.2.1. Global Glioblastoma Multiforme Market, By Temozolomide, By Region, 2019-2032 (US$ Mn)
10.2.2. Market Dynamics for Temozolomide
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Carmustine
10.3.1. Global Glioblastoma Multiforme Market, By Carmustine, By Region, 2019-2032 (US$ Mn)
10.3.2. Market Dynamics for Carmustine
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Lomustine
10.4.1. Global Glioblastoma Multiforme Market, By Lomustine, By Region, 2019-2032 (US$ Mn)
10.4.2. Market Dynamics for Lomustine
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
10.5. Others
10.5.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
10.5.2. Market Dynamics for Others
10.5.2.1. Drivers
10.5.2.2. Restraints
10.5.2.3. Opportunities
10.5.2.4. Trends
11. Global Glioblastoma Multiforme Market, By Immunotherapy Agents
11.1. Global Glioblastoma Multiforme Market Overview, by Immunotherapy Agents
11.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Immunotherapy Agents, 2023 Vs 2032 (in %)
11.2. Checkpoint Inhibitors
11.2.1. Global Glioblastoma Multiforme Market, By Checkpoint Inhibitors, By Region, 2019-2032 (US$ Mn)
11.2.2. Market Dynamics for Checkpoint Inhibitors
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Vaccines
11.3.1. Global Glioblastoma Multiforme Market, By Vaccines, By Region, 2019-2032 (US$ Mn)
11.3.2. Market Dynamics for Vaccines
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends
11.4. Others
11.4.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
11.4.2. Market Dynamics for Others
11.4.2.1. Drivers
11.4.2.2. Restraints
11.4.2.3. Opportunities
11.4.2.4. Trends
12. Global Glioblastoma Multiforme Market, By Targeted Therapy Agents
12.1. Global Glioblastoma Multiforme Market Overview, by Targeted Therapy Agents
12.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Targeted Therapy Agents, 2023 Vs 2032 (in %)
12.2. Bevacizumab
12.2.1. Global Glioblastoma Multiforme Market, By Bevacizumab, By Region, 2019-2032 (US$ Mn)
12.2.2. Market Dynamics for Bevacizumab
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Erlotinib
12.3.1. Global Glioblastoma Multiforme Market, By Erlotinib, By Region, 2019-2032 (US$ Mn)
12.3.2. Market Dynamics for Erlotinib
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
12.4. Others
12.4.1. Global Glioblastoma Multiforme Market, By Others, By Region, 2019-2032 (US$ Mn)
12.4.2. Market Dynamics for Others
12.4.2.1. Drivers
12.4.2.2. Restraints
12.4.2.3. Opportunities
12.4.2.4. Trends
13. Global Glioblastoma Multiforme Market, By Clinical Trial Phase
13.1. Global Glioblastoma Multiforme Market Overview, by Clinical Trial Phase
13.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Clinical Trial Phase, 2023 Vs 2032 (in %)
13.2. Phase I
13.2.1. Global Glioblastoma Multiforme Market, By Phase I, By Region, 2019-2032 (US$ Mn)
13.2.2. Market Dynamics for Phase I
13.2.2.1. Drivers
13.2.2.2. Restraints
13.2.2.3. Opportunities
13.2.2.4. Trends
13.3. Phase II
13.3.1. Global Glioblastoma Multiforme Market, By Phase II, By Region, 2019-2032 (US$ Mn)
13.3.2. Market Dynamics for Phase II
13.3.2.1. Drivers
13.3.2.2. Restraints
13.3.2.3. Opportunities
13.3.2.4. Trends
13.4. Phase III
13.4.1. Global Glioblastoma Multiforme Market, By Phase III, By Region, 2019-2032 (US$ Mn)
13.4.2. Market Dynamics for Phase III
13.4.2.1. Drivers
13.4.2.2. Restraints
13.4.2.3. Opportunities
13.4.2.4. Trends
13.5. Phase IV
13.5.1. Global Glioblastoma Multiforme Market, By Phase IV, By Region, 2019-2032 (US$ Mn)
13.5.2. Market Dynamics for Phase IV
13.5.2.1. Drivers
13.5.2.2. Restraints
13.5.2.3. Opportunities
13.5.2.4. Trends
14. Global Glioblastoma Multiforme Market, By Diagnostic Tools
14.1. Global Glioblastoma Multiforme Market Overview, by Diagnostic Tools
14.1.1. Global Glioblastoma Multiforme Market Revenue Share, By Diagnostic Tools, 2023 Vs 2032 (in %)
14.2. MRI
14.2.1. Global Glioblastoma Multiforme Market, By MRI, By Region, 2019-2032 (US$ Mn)
14.2.2. Market Dynamics for MRI
14.2.2.1. Drivers
14.2.2.2. Restraints
14.2.2.3. Opportunities
14.2.2.4. Trends
14.3. CT Scan
14.3.1. Global Glioblastoma Multiforme Market, By CT Scan, By Region, 2019-2032 (US$ Mn)
14.3.2. Market Dynamics for CT Scan
14.3.2.1. Drivers
14.3.2.2. Restraints
14.3.2.3. Opportunities
14.3.2.4. Trends
14.4. Biopsy
14.4.1. Global Glioblastoma Multiforme Market, By Biopsy, By Region, 2019-2032 (US$ Mn)
14.4.2. Market Dynamics for Biopsy
14.4.2.1. Drivers
14.4.2.2. Restraints
14.4.2.3. Opportunities
14.4.2.4. Trends
15. Global Glioblastoma Multiforme Market, By Region
15.1. Global Glioblastoma Multiforme Market Overview, by Region
15.1.1. Global Glioblastoma Multiforme Market, By Region, 2023 vs 2032 (in%)
15.2. Surgery
15.2.1. Global Glioblastoma Multiforme Market, By Surgery, 2019-2032 (US$ Mn)
15.3. End-User
15.3.1. Global Glioblastoma Multiforme Market, By End-User, 2019-2032 (US$ Mn)
15.4. Drug Class
15.4.1. Global Glioblastoma Multiforme Market, By Drug Class, 2019-2032 (US$ Mn)
15.5. Immunotherapy Agents
15.5.1. Global Glioblastoma Multiforme Market, By Immunotherapy Agents, 2019-2032 (US$ Mn)
15.6. Targeted Therapy Agents
15.6.1. Global Glioblastoma Multiforme Market, By Targeted Therapy Agents, 2019-2032 (US$ Mn)
15.7. Clinical Trial Phase
15.7.1. Global Glioblastoma Multiforme Market, By Clinical Trial Phase, 2019-2032 (US$ Mn)
15.8. Diagnostic Tools
15.8.1. Global Glioblastoma Multiforme Market, By Diagnostic Tools, 2019-2032 (US$ Mn)
16. North America Glioblastoma Multiforme Market Analysis
16.1. Overview
16.1.1. Market Dynamics for North America
16.1.1.1. Drivers
16.1.1.2. Restraints
16.1.1.3. Opportunities
16.1.1.4. Trends
16.2. North America Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. North America Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. North America Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. North America Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
16.5.1. Overview
16.5.2. SRC Analysis
16.6. North America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
16.6.1. Overview
16.6.2. SRC Analysis
16.7. North America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
16.7.1. Overview
16.7.2. SRC Analysis
16.8. North America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
16.8.1. Overview
16.8.2. SRC Analysis
16.9. North America Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
16.9.1. North America Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
16.9.2. U.S.
16.9.3. Canada
16.9.4. Mexico
17. Europe Glioblastoma Multiforme Market Analysis
17.1. Overview
17.1.1. Market Dynamics for North America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. Europe Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. Europe Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. Europe Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
17.6.1. Overview
17.6.2. SRC Analysis
17.7. Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
17.7.1. Overview
17.7.2. SRC Analysis
17.8. Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
17.8.1. Overview
17.8.2. SRC Analysis
17.9. Europe Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
17.9.1. Europe Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
17.9.2. UK
17.9.3. France
17.9.4. Germany
17.9.5. Italy
17.9.6. Spain
17.9.7. Benelux
17.9.8. Russia
17.9.9. Rest of Europe
18. Asia Pacific Glioblastoma Multiforme Market Analysis
18.1. Overview
18.1.1. Market Dynamics for North America
18.1.1.1. Drivers
18.1.1.2. Restraints
18.1.1.3. Opportunities
18.1.1.4. Trends
18.2. Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
18.2.1. Overview
18.2.2. SRC Analysis
18.3. Asia Pacific Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
18.3.1. Overview
18.3.2. SRC Analysis
18.4. Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
18.4.1. Overview
18.4.2. SRC Analysis
18.5. Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
18.5.1. Overview
18.5.2. SRC Analysis
18.6. Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
18.6.1. Overview
18.6.2. SRC Analysis
18.7. Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
18.7.1. Overview
18.7.2. SRC Analysis
18.8. Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
18.8.1. Overview
18.8.2. SRC Analysis
18.9. Asia Pacific Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
18.9.1. Asia Pacific Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
18.9.2. China
18.9.3. Japan
18.9.4. India
18.9.5. South Korea
18.9.6. South East Asia
18.9.7. Rest of Asia Pacific
19. Latin America Glioblastoma Multiforme Market Analysis
19.1. Overview
19.1.1. Market Dynamics for North America
19.1.1.1. Drivers
19.1.1.2. Restraints
19.1.1.3. Opportunities
19.1.1.4. Trends
19.2. Latin America Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
19.2.1. Overview
19.2.2. SRC Analysis
19.3. Latin America Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
19.3.1. Overview
19.3.2. SRC Analysis
19.4. Latin America Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
19.4.1. Overview
19.4.2. SRC Analysis
19.5. Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
19.5.1. Overview
19.5.2. SRC Analysis
19.6. Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
19.6.1. Overview
19.6.2. SRC Analysis
19.7. Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
19.7.1. Overview
19.7.2. SRC Analysis
19.8. Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
19.8.1. Overview
19.8.2. SRC Analysis
19.9. Latin America Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
19.9.1. Latin America Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
19.9.2. Brazil
19.9.3. Argentina
19.9.4. Rest of Latin America
20. Middle East Glioblastoma Multiforme Market Analysis
20.1. Overview
20.1.1. Market Dynamics for North America
20.1.1.1. Drivers
20.1.1.2. Restraints
20.1.1.3. Opportunities
20.1.1.4. Trends
20.2. Middle East Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
20.2.1. Overview
20.2.2. SRC Analysis
20.3. Middle East Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
20.3.1. Overview
20.3.2. SRC Analysis
20.4. Middle East Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
20.4.1. Overview
20.4.2. SRC Analysis
20.5. Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
20.5.1. Overview
20.5.2. SRC Analysis
20.6. Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
20.6.1. Overview
20.6.2. SRC Analysis
20.7. Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
20.7.1. Overview
20.7.2. SRC Analysis
20.8. Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
20.8.1. Overview
20.8.2. SRC Analysis
20.9. Middle East Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
20.9.1. Middle East Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
20.9.2. UAE
20.9.3. Saudi Arabia
20.9.4. Rest of Middle East
21. Africa Glioblastoma Multiforme Market Analysis
21.1. Overview
21.1.1. Market Dynamics for North America
21.1.1.1. Drivers
21.1.1.2. Restraints
21.1.1.3. Opportunities
21.1.1.4. Trends
21.2. Africa Glioblastoma Multiforme Market, by Surgery, 2019-2032(US$ Mn)
21.2.1. Overview
21.2.2. SRC Analysis
21.3. Africa Glioblastoma Multiforme Market, by End-User, 2019-2032(US$ Mn)
21.3.1. Overview
21.3.2. SRC Analysis
21.4. Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2032(US$ Mn)
21.4.1. Overview
21.4.2. SRC Analysis
21.5. Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, 2019-2032(US$ Mn)
21.5.1. Overview
21.5.2. SRC Analysis
21.6. Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2032(US$ Mn)
21.6.1. Overview
21.6.2. SRC Analysis
21.7. Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2032(US$ Mn)
21.7.1. Overview
21.7.2. SRC Analysis
21.8. Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2032(US$ Mn)
21.8.1. Overview
21.8.2. SRC Analysis
21.9. Africa Glioblastoma Multiforme Market, by Country, 2019-2032 (US$ Mn)
21.9.1. Middle East Glioblastoma Multiforme Market, by Country, 2023 Vs 2032 (in%)
21.9.2. South Africa
21.9.3. Egypt
21.9.4. Rest of Africa
22. Company Profiles
22.1. Merck & Co. Inc
22.1.1. Company Overview
22.1.2. Products/Services Portfolio
22.1.3. Geographical Presence
22.1.4. SWOT Analysis
22.1.5. Financial Summary
22.1.5.1. Market Revenue and Net Profit (2019-2023)
22.1.5.2. Business Segment Revenue Analysis
22.1.5.3. Geographical Revenue Analysis
22.2. Amgen Inc
22.3. F. Hoffmann-La Roche Ltd
22.4. Pfizer Inc
22.5. Teva Pharmaceutical Industries Ltd
22.6. Sun Pharmaceutical Industries Ltd
22.7. Arbor Pharmaceuticals LLC
22.8. Amneal Pharmaceuticals
22.9. Karyopharm Therapeutics Inc
22.10. Others
23. Research Methodology
23.1. Research Methodology
23.2. Phase I – Secondary Research
23.3. Phase II – Data Modelling
23.3.1. Company Share Analysis Model
23.3.2. Revenue Based Modelling
23.4. Phase III – Primary Research
23.5. Research Limitations
23.5.1. Assumptions
List of Figures
FIG. 1 Global Glioblastoma Multiforme Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Glioblastoma Multiforme Market Segmentation
FIG. 4 Global Glioblastoma Multiforme Market, by Surgery, 2023 (US$ Mn)
FIG. 5 Global Glioblastoma Multiforme Market, by End-User, 2023 (US$ Mn)
FIG. 6 Global Glioblastoma Multiforme Market, by Drug Class, 2023 (US$ Mn)
FIG. 7 Global Glioblastoma Multiforme Market, by Immunotherapy Agents, 2023 (US$ Mn)
FIG. 8 Global Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2023 (US$ Mn)
FIG. 9 Global Glioblastoma Multiforme Market, by Clinical Trial Phase, 2023 (US$ Mn)
FIG. 10 Global Glioblastoma Multiforme Market, by Diagnostic Tools, 2023 (US$ Mn)
FIG. 11 Global Glioblastoma Multiforme Market, by Geography, 2023 (US$ Mn)
FIG. 12 Attractive Investment Proposition, by Surgery, 2023
FIG. 13 Attractive Investment Proposition, by End-User, 2023
FIG. 14 Attractive Investment Proposition, by Drug Class, 2023
FIG. 15 Attractive Investment Proposition, by Immunotherapy Agents, 2023
FIG. 16 Attractive Investment Proposition, by Targeted Therapy Agents, 2023
FIG. 17 Attractive Investment Proposition, by Clinical Trial Phase, 2023
FIG. 18 Attractive Investment Proposition, by Diagnostic Tools, 2023
FIG. 19 Attractive Investment Proposition, by Geography, 2023
FIG. 20 Global Market Share Analysis of Key Glioblastoma Multiforme Market Manufacturers, 2023
FIG. 21 Global Market Positioning of Key Glioblastoma Multiforme Market Manufacturers, 2023
FIG. 22 Global Glioblastoma Multiforme Market Value Contribution, By Surgery, 2023 & 2032 (Value %)
FIG. 23 Global Glioblastoma Multiforme Market, by Radiation Therapy, Value, 2019-2032 (US$ Mn)
FIG. 24 Global Glioblastoma Multiforme Market, by Chemotherapy, Value, 2019-2032 (US$ Mn)
FIG. 25 Global Glioblastoma Multiforme Market, by Immunotherapy, Value, 2019-2032 (US$ Mn)
FIG. 26 Global Glioblastoma Multiforme Market, by Targeted Therapy, Value, 2019-2032 (US$ Mn)
FIG. 27 Global Glioblastoma Multiforme Market, by Tumor Treating Fields (TTF) Therapy, Value, 2019-2032 (US$ Mn)
FIG. 28 Global Glioblastoma Multiforme Market, by Supportive Care, Value, 2019-2032 (US$ Mn)
FIG. 29 Global Glioblastoma Multiforme Market Value Contribution, By End-User, 2023 & 2032 (Value %)
FIG. 30 Global Glioblastoma Multiforme Market, by Hospitals, Value, 2019-2032 (US$ Mn)
FIG. 31 Global Glioblastoma Multiforme Market, by Cancer Research Institutes, Value, 2019-2032 (US$ Mn)
FIG. 32 Global Glioblastoma Multiforme Market, by Ambulatory Surgical Centers, Value, 2019-2032 (US$ Mn)
FIG. 33 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 34 Global Glioblastoma Multiforme Market Value Contribution, By Drug Class, 2023 & 2032 (Value %)
FIG. 35 Global Glioblastoma Multiforme Market, by Temozolomide, Value, 2019-2032 (US$ Mn)
FIG. 36 Global Glioblastoma Multiforme Market, by Carmustine, Value, 2019-2032 (US$ Mn)
FIG. 37 Global Glioblastoma Multiforme Market, by Lomustine, Value, 2019-2032 (US$ Mn)
FIG. 38 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 39 Global Glioblastoma Multiforme Market Value Contribution, By Immunotherapy Agents, 2023 & 2032 (Value %)
FIG. 40 Global Glioblastoma Multiforme Market, by Checkpoint Inhibitors, Value, 2019-2032 (US$ Mn)
FIG. 41 Global Glioblastoma Multiforme Market, by Vaccines, Value, 2019-2032 (US$ Mn)
FIG. 42 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 43 Global Glioblastoma Multiforme Market Value Contribution, By Targeted Therapy Agents, 2023 & 2032 (Value %)
FIG. 44 Global Glioblastoma Multiforme Market, by Bevacizumab, Value, 2019-2032 (US$ Mn)
FIG. 45 Global Glioblastoma Multiforme Market, by Erlotinib, Value, 2019-2032 (US$ Mn)
FIG. 46 Global Glioblastoma Multiforme Market, by Others, Value, 2019-2032 (US$ Mn)
FIG. 47 Global Glioblastoma Multiforme Market Value Contribution, By Clinical Trial Phase, 2023 & 2032 (Value %)
FIG. 48 Global Glioblastoma Multiforme Market, by Phase I, Value, 2019-2032 (US$ Mn)
FIG. 49 Global Glioblastoma Multiforme Market, by Phase II, Value, 2019-2032 (US$ Mn)
FIG. 50 Global Glioblastoma Multiforme Market, by Phase III, Value, 2019-2032 (US$ Mn)
FIG. 51 Global Glioblastoma Multiforme Market, by Phase IV, Value, 2019-2032 (US$ Mn)
FIG. 52 Global Glioblastoma Multiforme Market Value Contribution, By Diagnostic Tools, 2023 & 2032 (Value %)
FIG. 53 Global Glioblastoma Multiforme Market, by MRI, Value, 2019-2032 (US$ Mn)
FIG. 54 Global Glioblastoma Multiforme Market, by CT Scan, Value, 2019-2032 (US$ Mn)
FIG. 55 Global Glioblastoma Multiforme Market, by Biopsy, Value, 2019-2032 (US$ Mn)
FIG. 56 North America Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 57 U.S. Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 58 Canada Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 59 Mexico Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 60 Europe Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 61 Germany Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 62 France Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 63 U.K. Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 64 Italy Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 65 Spain Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 66 Benelux Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 67 Russia Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 68 Rest of Europe Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 69 Asia Pacific Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 70 China Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 71 Japan Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 72 India Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 73 South Korea Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 74 South-East Asia Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 75 Rest of Asia Pacific Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 76 Latin America Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 77 Brazil Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 78 Argentina Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 79 Rest of Latin America Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 80 Middle East Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 81 UAE Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 82 Saudi Arabia Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 83 Rest of Middle East Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 84 Africa Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 85 South Africa Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 86 Egypt Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
FIG. 87 Rest of Africa Glioblastoma Multiforme Market, 2019-2032 (US$ Mn)
List of Tables
TABLE 1 Market Snapshot: Global Glioblastoma Multiforme Market
TABLE 2 Global Glioblastoma Multiforme Market: Market Drivers Impact Analysis
TABLE 3 Global Glioblastoma Multiforme Market: Market Restraints Impact Analysis
TABLE 4 Global Glioblastoma Multiforme Market, by Competitive Benchmarking, 2023
TABLE 5 Global Glioblastoma Multiforme Market, by Geographical Presence Analysis, 2023
TABLE 6 Global Glioblastoma Multiforme Market, by Key Strategies Analysis, 2023
TABLE 7 Global Glioblastoma Multiforme Market, by Radiation Therapy, By Region, 2019-2023 (US$ Mn)
TABLE 8 Global Glioblastoma Multiforme Market, by Radiation Therapy, By Region, 2024-2032 (US$ Mn)
TABLE 9 Global Glioblastoma Multiforme Market, by Chemotherapy, By Region, 2019-2023 (US$ Mn)
TABLE 10 Global Glioblastoma Multiforme Market, by Chemotherapy, By Region, 2024-2032 (US$ Mn)
TABLE 11 Global Glioblastoma Multiforme Market, by Immunotherapy, By Region, 2019-2023 (US$ Mn)
TABLE 12 Global Glioblastoma Multiforme Market, by Immunotherapy, By Region, 2024-2032 (US$ Mn)
TABLE 13 Global Glioblastoma Multiforme Market, by Targeted Therapy, By Region, 2019-2023 (US$ Mn)
TABLE 14 Global Glioblastoma Multiforme Market, by Targeted Therapy, By Region, 2024-2032 (US$ Mn)
TABLE 15 Global Glioblastoma Multiforme Market, by Tumor Treating Fields (TTF) Therapy, By Region, 2019-2023 (US$ Mn)
TABLE 16 Global Glioblastoma Multiforme Market, by Tumor Treating Fields (TTF) Therapy, By Region, 2024-2032 (US$ Mn)
TABLE 17 Global Glioblastoma Multiforme Market, by Supportive Care, By Region, 2019-2023 (US$ Mn)
TABLE 18 Global Glioblastoma Multiforme Market, by Supportive Care, By Region, 2024-2032 (US$ Mn)
TABLE 19 Global Glioblastoma Multiforme Market, by Hospitals, By Region, 2019-2023 (US$ Mn)
TABLE 20 Global Glioblastoma Multiforme Market, by Hospitals, By Region, 2024-2032 (US$ Mn)
TABLE 21 Global Glioblastoma Multiforme Market, by Cancer Research Institutes, By Region, 2019-2023 (US$ Mn)
TABLE 22 Global Glioblastoma Multiforme Market, by Cancer Research Institutes, By Region, 2024-2032 (US$ Mn)
TABLE 23 Global Glioblastoma Multiforme Market, by Ambulatory Surgical Centers, By Region, 2019-2023 (US$ Mn)
TABLE 24 Global Glioblastoma Multiforme Market, by Ambulatory Surgical Centers, By Region, 2024-2032 (US$ Mn)
TABLE 25 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 26 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 27 Global Glioblastoma Multiforme Market, by Temozolomide, By Region, 2019-2023 (US$ Mn)
TABLE 28 Global Glioblastoma Multiforme Market, by Temozolomide, By Region, 2024-2032 (US$ Mn)
TABLE 29 Global Glioblastoma Multiforme Market, by Carmustine, By Region, 2019-2023 (US$ Mn)
TABLE 30 Global Glioblastoma Multiforme Market, by Carmustine, By Region, 2024-2032 (US$ Mn)
TABLE 31 Global Glioblastoma Multiforme Market, by Lomustine, By Region, 2019-2023 (US$ Mn)
TABLE 32 Global Glioblastoma Multiforme Market, by Lomustine, By Region, 2024-2032 (US$ Mn)
TABLE 33 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 34 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 35 Global Glioblastoma Multiforme Market, by Checkpoint Inhibitors, By Region, 2019-2023 (US$ Mn)
TABLE 36 Global Glioblastoma Multiforme Market, by Checkpoint Inhibitors, By Region, 2024-2032 (US$ Mn)
TABLE 37 Global Glioblastoma Multiforme Market, by Vaccines, By Region, 2019-2023 (US$ Mn)
TABLE 38 Global Glioblastoma Multiforme Market, by Vaccines, By Region, 2024-2032 (US$ Mn)
TABLE 39 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 40 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 41 Global Glioblastoma Multiforme Market, by Bevacizumab, By Region, 2019-2023 (US$ Mn)
TABLE 42 Global Glioblastoma Multiforme Market, by Bevacizumab, By Region, 2024-2032 (US$ Mn)
TABLE 43 Global Glioblastoma Multiforme Market, by Erlotinib, By Region, 2019-2023 (US$ Mn)
TABLE 44 Global Glioblastoma Multiforme Market, by Erlotinib, By Region, 2024-2032 (US$ Mn)
TABLE 45 Global Glioblastoma Multiforme Market, by Others, By Region, 2019-2023 (US$ Mn)
TABLE 46 Global Glioblastoma Multiforme Market, by Others, By Region, 2024-2032 (US$ Mn)
TABLE 47 Global Glioblastoma Multiforme Market, by Phase I, By Region, 2019-2023 (US$ Mn)
TABLE 48 Global Glioblastoma Multiforme Market, by Phase I, By Region, 2024-2032 (US$ Mn)
TABLE 49 Global Glioblastoma Multiforme Market, by Phase II, By Region, 2019-2023 (US$ Mn)
TABLE 50 Global Glioblastoma Multiforme Market, by Phase II, By Region, 2024-2032 (US$ Mn)
TABLE 51 Global Glioblastoma Multiforme Market, by Phase III, By Region, 2019-2023 (US$ Mn)
TABLE 52 Global Glioblastoma Multiforme Market, by Phase III, By Region, 2024-2032 (US$ Mn)
TABLE 53 Global Glioblastoma Multiforme Market, by Phase IV, By Region, 2019-2023 (US$ Mn)
TABLE 54 Global Glioblastoma Multiforme Market, by Phase IV, By Region, 2024-2032 (US$ Mn)
TABLE 55 Global Glioblastoma Multiforme Market, by MRI, By Region, 2019-2023 (US$ Mn)
TABLE 56 Global Glioblastoma Multiforme Market, by MRI, By Region, 2024-2032 (US$ Mn)
TABLE 57 Global Glioblastoma Multiforme Market, by CT Scan, By Region, 2019-2023 (US$ Mn)
TABLE 58 Global Glioblastoma Multiforme Market, by CT Scan, By Region, 2024-2032 (US$ Mn)
TABLE 59 Global Glioblastoma Multiforme Market, by Biopsy, By Region, 2019-2023 (US$ Mn)
TABLE 60 Global Glioblastoma Multiforme Market, by Biopsy, By Region, 2024-2032 (US$ Mn)
TABLE 61 Global Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 62 Global Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 63 Global Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 64 Global Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 65 Global Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 66 Global Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 67 Global Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 68 Global Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 69 Global Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 70 Global Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 71 Global Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 72 Global Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 73 Global Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 74 Global Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 75 Global Glioblastoma Multiforme Market, by Region, 2019-2023 (US$ Mn)
TABLE 76 Global Glioblastoma Multiforme Market, by Region, 2024-2032 (US$ Mn)
TABLE 77 North America Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 78 North America Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 79 North America Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 80 North America Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 81 North America Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 82 North America Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 83 North America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 84 North America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 85 North America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 86 North America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 87 North America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 88 North America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 89 North America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 90 North America Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 91 North America Glioblastoma Multiforme Market, by Country, 2019-2023 (US$ Mn)
TABLE 92 North America Glioblastoma Multiforme Market, by Country, 2024-2032 (US$ Mn)
TABLE 93 United States Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 94 United States Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 95 United States Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 96 United States Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 97 United States Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 98 United States Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 99 United States Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 100 United States Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 101 United States Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 102 United States Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 103 United States Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 104 United States Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 105 United States Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 106 United States Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 107 Canada Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 108 Canada Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 109 Canada Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 110 Canada Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 111 Canada Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 112 Canada Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 113 Canada Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 114 Canada Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 115 Canada Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 116 Canada Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 117 Canada Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 118 Canada Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 119 Canada Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 120 Canada Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 121 Mexico Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 122 Mexico Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 123 Mexico Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 124 Mexico Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 125 Mexico Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 126 Mexico Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 127 Mexico Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 128 Mexico Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 129 Mexico Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 130 Mexico Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 131 Mexico Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 132 Mexico Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 133 Mexico Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 134 Mexico Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 135 Europe Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 136 Europe Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 137 Europe Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 138 Europe Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 139 Europe Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 140 Europe Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 141 Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 142 Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 143 Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 144 Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 145 Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 146 Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 147 Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 148 Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 149 Europe Glioblastoma Multiforme Market, by Country, 2019-2023 (US$ Mn)
TABLE 150 Europe Glioblastoma Multiforme Market, by Country, 2024-2032 (US$ Mn)
TABLE 151 Germany Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 152 Germany Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 153 Germany Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 154 Germany Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 155 Germany Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 156 Germany Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 157 Germany Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 158 Germany Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 159 Germany Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 160 Germany Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 161 Germany Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 162 Germany Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 163 Germany Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 164 Germany Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 165 France Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 166 France Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 167 France Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 168 France Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 169 France Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 170 France Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 171 France Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 172 France Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 173 France Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 174 France Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 175 France Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 176 France Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 177 France Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 178 France Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 179 United Kingdom Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 180 United Kingdom Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 181 United Kingdom Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 182 United Kingdom Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 183 United Kingdom Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 184 United Kingdom Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 185 United Kingdom Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 186 United Kingdom Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 187 United Kingdom Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 188 United Kingdom Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 189 United Kingdom Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 190 United Kingdom Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 191 United Kingdom Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 192 United Kingdom Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 193 Italy Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 194 Italy Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 195 Italy Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 196 Italy Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 197 Italy Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 198 Italy Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 199 Italy Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 200 Italy Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 201 Italy Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 202 Italy Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 203 Italy Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 204 Italy Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 205 Italy Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 206 Italy Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 207 Spain Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 208 Spain Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 209 Spain Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 210 Spain Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 211 Spain Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 212 Spain Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 213 Spain Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 214 Spain Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 215 Spain Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 216 Spain Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 217 Spain Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 218 Spain Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 219 Spain Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 220 Spain Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 221 Benelux Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 222 Benelux Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 223 Benelux Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 224 Benelux Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 225 Benelux Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 226 Benelux Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 227 Benelux Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 228 Benelux Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 229 Benelux Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 230 Benelux Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 231 Benelux Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 232 Benelux Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 233 Benelux Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 234 Benelux Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 235 Russia Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 236 Russia Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 237 Russia Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 238 Russia Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 239 Russia Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 240 Russia Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 241 Russia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 242 Russia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 243 Russia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 244 Russia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 245 Russia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 246 Russia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 247 Russia Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 248 Russia Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 249 Rest of Europe Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 250 Rest of Europe Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 251 Rest of Europe Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 252 Rest of Europe Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 253 Rest of Europe Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 254 Rest of Europe Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 255 Rest of Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 256 Rest of Europe Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 257 Rest of Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 258 Rest of Europe Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 259 Rest of Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 260 Rest of Europe Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 261 Rest of Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 262 Rest of Europe Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 263 Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 264 Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 265 Asia Pacific Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 266 Asia Pacific Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 267 Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 268 Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 269 Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 270 Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 271 Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 272 Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 273 Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 274 Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 275 Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 276 Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 277 China Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 278 China Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 279 China Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 280 China Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 281 China Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 282 China Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 283 China Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 284 China Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 285 China Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 286 China Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 287 China Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 288 China Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 289 China Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 290 China Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 291 Japan Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 292 Japan Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 293 Japan Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 294 Japan Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 295 Japan Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 296 Japan Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 297 Japan Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 298 Japan Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 299 Japan Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 300 Japan Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 301 Japan Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 302 Japan Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 303 Japan Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 304 Japan Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 305 India Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 306 India Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 307 India Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 308 India Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 309 India Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 310 India Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 311 India Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 312 India Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 313 India Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 314 India Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 315 India Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 316 India Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 317 India Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 318 India Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 319 South Korea Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 320 South Korea Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 321 South Korea Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 322 South Korea Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 323 South Korea Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 324 South Korea Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 325 South Korea Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 326 South Korea Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 327 South Korea Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 328 South Korea Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 329 South Korea Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 330 South Korea Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 331 South Korea Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 332 South Korea Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 333 South-East Asia Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 334 South-East Asia Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 335 South-East Asia Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 336 South-East Asia Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 337 South-East Asia Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 338 South-East Asia Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 339 South-East Asia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 340 South-East Asia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 341 South-East Asia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 342 South-East Asia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 343 South-East Asia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 344 South-East Asia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 345 South-East Asia Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 346 South-East Asia Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 347 Rest of Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 348 Rest of Asia Pacific Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 349 Rest of Asia Pacific Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 350 Rest of Asia Pacific Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 351 Rest of Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 352 Rest of Asia Pacific Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 353 Rest of Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 354 Rest of Asia Pacific Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 355 Rest of Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 356 Rest of Asia Pacific Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 357 Rest of Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 358 Rest of Asia Pacific Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 359 Rest of Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 360 Rest of Asia Pacific Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 361 Latin America Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 362 Latin America Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 363 Latin America Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 364 Latin America Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 365 Latin America Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 366 Latin America Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 367 Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 368 Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 369 Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 370 Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 371 Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 372 Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 373 Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 374 Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 375 Brazil Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 376 Brazil Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 377 Brazil Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 378 Brazil Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 379 Brazil Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 380 Brazil Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 381 Brazil Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 382 Brazil Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 383 Brazil Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 384 Brazil Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 385 Brazil Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 386 Brazil Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 387 Brazil Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 388 Brazil Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 389 Argentina Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 390 Argentina Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 391 Argentina Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 392 Argentina Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 393 Argentina Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 394 Argentina Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 395 Argentina Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 396 Argentina Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 397 Argentina Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 398 Argentina Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 399 Argentina Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 400 Argentina Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 401 Argentina Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 402 Argentina Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 403 Rest of Latin America Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 404 Rest of Latin America Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 405 Rest of Latin America Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 406 Rest of Latin America Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 407 Rest of Latin America Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 408 Rest of Latin America Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 409 Rest of Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 410 Rest of Latin America Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 411 Rest of Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 412 Rest of Latin America Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 413 Rest of Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 414 Rest of Latin America Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 415 Rest of Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 416 Rest of Latin America Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 417 Middle East Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 418 Middle East Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 419 Middle East Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 420 Middle East Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 421 Middle East Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 422 Middle East Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 423 Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 424 Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 425 Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 426 Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 427 Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 428 Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 429 Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 430 Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 431 UAE Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 432 UAE Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 433 UAE Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 434 UAE Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 435 UAE Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 436 UAE Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 437 UAE Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 438 UAE Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 439 UAE Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 440 UAE Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 441 UAE Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 442 UAE Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 443 UAE Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 444 UAE Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 445 Saudi Arabia Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 446 Saudi Arabia Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 447 Saudi Arabia Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 448 Saudi Arabia Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 449 Saudi Arabia Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 450 Saudi Arabia Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 451 Saudi Arabia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 452 Saudi Arabia Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 453 Saudi Arabia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 454 Saudi Arabia Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 455 Saudi Arabia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 456 Saudi Arabia Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 457 Saudi Arabia Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 458 Saudi Arabia Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 459 Rest of Middle East Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 460 Rest of Middle East Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 461 Rest of Middle East Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 462 Rest of Middle East Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 463 Rest of Middle East Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 464 Rest of Middle East Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 465 Rest of Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 466 Rest of Middle East Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 467 Rest of Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 468 Rest of Middle East Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 469 Rest of Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 470 Rest of Middle East Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 471 Rest of Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 472 Rest of Middle East Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 473 Africa Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 474 Africa Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 475 Africa Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 476 Africa Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 477 Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 478 Africa Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 479 Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 480 Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 481 Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 482 Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 483 Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 484 Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 485 Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 486 Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 487 South Africa Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 488 South Africa Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 489 South Africa Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 490 South Africa Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 491 South Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 492 South Africa Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 493 South Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 494 South Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 495 South Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 496 South Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 497 South Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 498 South Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 499 South Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 500 South Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 501 Egypt Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 502 Egypt Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 503 Egypt Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 504 Egypt Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 505 Egypt Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 506 Egypt Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 507 Egypt Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 508 Egypt Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 509 Egypt Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 510 Egypt Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 511 Egypt Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 512 Egypt Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 513 Egypt Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 514 Egypt Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)
TABLE 515 Rest of Africa Glioblastoma Multiforme Market, by Surgery, 2019-2023 (US$ Mn)
TABLE 516 Rest of Africa Glioblastoma Multiforme Market, by Surgery, 2024-2032 (US$ Mn)
TABLE 517 Rest of Africa Glioblastoma Multiforme Market, by End-User, 2019-2023 (US$ Mn)
TABLE 518 Rest of Africa Glioblastoma Multiforme Market, by End-User, 2024-2032 (US$ Mn)
TABLE 519 Rest of Africa Glioblastoma Multiforme Market, by Drug Class, 2019-2023 (US$ Mn)
TABLE 520 Rest of Africa Glioblastoma Multiforme Market, by Drug Class, 2024-2032 (US$ Mn)
TABLE 521 Rest of Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2019-2023 (US$ Mn)
TABLE 522 Rest of Africa Glioblastoma Multiforme Market, by Immunotherapy Agents, By Region, 2024-2032 (US$ Mn)
TABLE 523 Rest of Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2019-2023 (US$ Mn)
TABLE 524 Rest of Africa Glioblastoma Multiforme Market, by Targeted Therapy Agents, 2024-2032 (US$ Mn)
TABLE 525 Rest of Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2019-2023 (US$ Mn)
TABLE 526 Rest of Africa Glioblastoma Multiforme Market, by Clinical Trial Phase, 2024-2032 (US$ Mn)
TABLE 527 Rest of Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2019-2023 (US$ Mn)
TABLE 528 Rest of Africa Glioblastoma Multiforme Market, by Diagnostic Tools, 2024-2032 (US$ Mn)